Volume 25, Number 7—July 2019
Synopsis
Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015
Table 5
Isolate no. | Site | Carbapenemase | Carbapenemase gene location | ST | Antimicrobial resistance pattern* |
---|---|---|---|---|---|
1 | New Mexico | IMP-18 | Plasmid | ST179 | AMK, CAZ, CAZ/AVI, CIP, DOR, FEP, GEN, IMI, LEV, MER, CEF/TAZ, TOB |
2 | New Mexico | VIM-2 | Chromosomal | ST308 | CAZ,† CAZ/AVI, CIP, DOR, GEN, IMI, LEV, MER, CEF/TAZ, TOB |
3 | Tennessee | HMB-2 | Chromosomal | ST235 | AMK, CAZ, CAZ/AVI, CIP, DOR, FEP, GEN, LEV, MER, PIP/TAZ, CEF/TAZ, TOB |
*Resistance pattern based on reference broth microdilution testing using 2019 Clinical and Laboratory Standards Institute interpretative criteria. AMK, amikacin; CAZ, ceftazidime; CAZ/AVI, ceftazidime/avibactam; CEF/TAZ, ceftolozane-tazobactam; CIP, ciprofloxacin; DOR, doripenem; FEP, cefepime; GEN, gentamicin; HMB, Hamburg metallo-β-lactamase; IMI, imipenem; IMP, active-on-imipenem; LEV, levofloxacin; MER, meropenem; PIP/TAZ, piperacillin/tazobactam; ST, sequence type; TOB, tobramycin; VIM, Verona integron mediated.
†Intermediate antimicrobial susceptibility.
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.